Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant

Mutations in ESR1 have been associated with resistance to aromatase inhibitor (AI) therapy in patients with ER+ metastatic breast cancer. Little is known of the impact of these mutations in patients receiving selective oestrogen receptor degrader (SERD) therapy. In this study, hotspot mutations in E...

Descripción completa

Detalles Bibliográficos
Autores principales: Spoerke, Jill M., Gendreau, Steven, Walter, Kimberly, Qiu, Jiaheng, Wilson, Timothy R., Savage, Heidi, Aimi, Junko, Derynck, Mika K., Chen, Meng, Chan, Iris T., Amler, Lukas C., Hampton, Garret M., Johnston, Stephen, Krop, Ian, Schmid, Peter, Lackner, Mark R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4869259/
https://www.ncbi.nlm.nih.gov/pubmed/27174596
http://dx.doi.org/10.1038/ncomms11579

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4869259/
https://www.ncbi.nlm.nih.gov/pubmed/27174596
http://dx.doi.org/10.1038/ncomms11579

Ejemplares similares